A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

The Glo-BNHL trial is trying to find better medicines for children and young people with B-cell non-Hodgkin Lymphoma (B-NHL) that does not go away (refractory B-NHL) or does but comes back again (relapsed B-NHL). B-NHL is a type of cancer that develops inside or outside of lymph nodes (glands) and organs such as the liver or spleen. Examples of B-NHL are Burkitt Lymphoma and Diffuse Large B Cell Lymphoma, which may be other names used to describe this type of cancer. It is very difficult to cure relapsed or refractory B-NHL. The medicines used now are very powerful with many side effects and o

Trial Details

NCT ID
NCT05991388
Phase
PHASE2 / PHASE3
Sponsor
University of Birmingham
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Odronextamab
  • Loncastuximab tesirine
  • Rituximab
  • Ifosfamide
  • Carboplatin
  • Etoposide
Locations (sample)
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Brisbane, Queensland, Australia|-27.46794,153.02809
  • Perth, Washington, Australia|-31.95224,115.8614
  • Vienna, Austria|48.20849,16.37208
  • Leuven, Belgium|50.87959,4.70093

Key Eligibility Criteria

  • Histologically proven mature B-NHL (Diffuse Large B-Cell Lymphoma (DLBCL), Burkitt Lymphoma/Leukaemia or atypical Burkitt/Burkitt-like lymphoma, pr…
  • Radiologically and/or histologically proven B-NHL in first relapse (only one prior line of therapy) or subsequent relapse (more than one prior line…
  • If relapse occurs more than two years after previous therapy, a biopsy must be performed
  • Evaluable disease as per the international paediatric non-Hodgkin Lymphoma response criteria, including:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →